What it is
Epithalon, also spelled epitalon, is a lab-made chain of just four amino acids: alanine, glutamic acid, aspartic acid and glycine. Its creators designed it as a simple synthetic stand-in for epithalamin, an extract of cattle pineal glands. The pineal gland is the small gland in the brain that makes the sleep hormone melatonin.
Epithalon is best known for laboratory reports that it switched on telomerase, the enzyme that rebuilds the protective caps on the ends of chromosomes, in human cells grown in dishes. That finding, and mouse lifespan experiments, explain its reputation as an “anti-ageing” peptide. Those results have not been shown in people. It is not an approved medicine in the United States.
Epitalon is H-Ala-Glu-Asp-Gly-OH (C14H22N4O9, 390.35 g/mol, CAS 307297-39-8). Its developers describe it as derived from the amino-acid composition of epithalamin, a low-molecular-weight polypeptide extract of bovine pineal gland; FDA treats the two as distinct substances and does not list epithalamin as a synonym.
No receptor has been identified. The developer group proposes that short peptides such as Ala-Glu-Asp-Gly enter the nucleus and bind DNA or histones to regulate gene expression, an epigenetic hypothesis supported mainly by modelling and in-vitro work. Reported in-vitro effects include induction of the telomerase catalytic subunit and telomere elongation in fibroblasts, and antioxidant and anti-inflammatory activity in cell models. In old female rhesus monkeys, the same group reported changes in the daily pattern of melatonin and cortisol; in isolated rat pineal glands, epitalon did not increase melatonin release (Djeridane et al. 2003, as summarised by FDA).
Pharmacokinetics are essentially unknown. The only distribution data are from a study giving fluorescently labelled epitalon intravenously to pregnant rabbits, which FDA said should be interpreted with caution because the signal was not shown to come from epitalon itself. FDA found no pharmacokinetic, acute toxicity, repeat-dose toxicity or reproductive toxicity studies, and no human pharmacokinetic data.
Who made it and when
Epithalon came out of the research programme of Vladimir Khavinson, a Russian gerontologist who, with Vladimir Morozov, made peptide extracts from animal organs such as the thymus and pineal gland. According to the FDA’s review, epithalon itself was first synthesised in the late 1980s under Khavinson’s direction. His group later became the St Petersburg Institute of Bioregulation and Gerontology, which has published most of the research on it. No pharmaceutical company has taken it through modern clinical development, and a US orphan-drug designation it received in 2010 ended in 2016.
FDA’s 2026 briefing document states that epitalon was first synthesised in the late 1980s by researchers under Professor Vladimir Khavinson in St Petersburg, as the putative active component of epithalamin. Epithalamin, the bovine pineal extract, and thymalin, a calf-thymus extract, are the two polypeptide preparations studied by Khavinson and Morozov in their 2003 elderly-cohort report.
Nearly all subsequent pharmacology, including the telomerase and mouse-lifespan work with V.N. Anisimov at the N.N. Petrov Institute of Oncology, comes from Khavinson’s institute and its collaborators; FDA noted that most pharmacological studies of epitalon “have been conducted and published by Dr. Khavinson’s research group in Russia”. Some key references cited by nominators are available only in Russian.
According to FDA, epitalon received a US orphan-drug designation for retinitis pigmentosa on 2010-09-02, which was withdrawn or revoked on 2016-01-06. An orphan designation is a development incentive, not an approval. No developer patent was verified for this article, so none is listed.
What the data say
Most of the evidence comes from cells and animals. In human fetal lung cells grown in the lab, the developers reported that epithalon switched on telomerase and lengthened telomeres. An independent British team reported similar telomere lengthening in several cell lines in 2025, including cancer cells. In mice, monthly injections did not lengthen average lifespan, though the longest-lived animals lived somewhat longer.
In people, the published work is small and almost all from the same Russian group. The best-known “longer life” reports in elderly people used epithalamin, the cattle-gland extract, not epithalon. A small 2020s study in 40 night-shift workers measured a melatonin by-product in urine, not sleep. No trial is registered on ClinicalTrials.gov.
In vitro: Khavinson et al. (2003) reported that epitalon (50 ng/mL, 4 days) induced hTERT expression, telomerase activity and telomere elongation in telomerase-negative human fetal fibroblasts. Al-Dulaimi et al. (2025, Brunel University London) reported dose-dependent telomere extension via hTERT upregulation in normal epithelial cells and fibroblasts, and via the telomerase-independent ALT pathway in breast-cancer lines. FDA cautioned that sustained telomerase activation could in principle favour malignant transformation.
Animals: in female SHR mice (54 per group) given 1 µg subcutaneously for 5 days monthly from 3 months of age, Anisimov et al. (2003) found no change in mean lifespan, a 12.3% longer maximum lifespan and less leukaemia, with no change in total tumour incidence. The studies used single fixed doses and females only.
Humans: Khavinson and Morozov (2003) reported 1.6–1.8-fold lower mortality over 6–8 years in elderly people given epithalamin, not epitalon, in a 266-person cohort without described randomisation or blinding. For epitalon itself, Ivko et al. randomised 40 women aged 40–50 on night shifts with low urinary 6-sulfatoxymelatonin to placebo or sublingual spray (0.5 mg/day, 20 days) and reported a 1.7-fold rise in the metabolite; blinding was not specified and sleep was not measured.
Regulatory picture
Approval: no medicine containing epithalon is approved by the FDA, and its orphan-drug designation for an inherited eye disease ended in 2016. Compounding: in September 2023 the FDA put it in “Category 2”, the group of substances pharmacies should not compound from, citing possible immune reactions and a lack of safety information. By April 2026 the FDA listed it as withdrawn from that category by its nominators. FDA staff reviewed it for insomnia and advised against allowing it, but in July 2026 an FDA advisory committee voted narrowly to recommend adding it to the list of allowed compounding ingredients. The vote is not binding, and the FDA had not made a final decision when this was written. Enforcement: a 2020 FDA warning letter to a compounding pharmacy named epitalon among ingredients it should not have compounded.
Approval: none. No US IND-stage programme could be verified; the 2010 orphan designation (retinitis pigmentosa) was withdrawn or revoked on 2016-01-06, according to FDA.
Compounding: “Epitalon” entered Category 2 of the interim 503A policy on 2023-09-29. FDA’s safety-risk page (updated 2026-04-22) lists it among substances withdrawn by the nominators, and it is not on the 503A bulks list (21 CFR 216.23), so this article records compounding status as unknown.
FDA’s 2026 briefing document evaluated epitalon free base and acetate for insomnia only; it did not evaluate the other nominated uses (anti-ageing, telomere lengthening and others) because the nominations lacked sufficient supporting information. It concluded that the criteria weigh against inclusion: characterisation data (impurities, aggregates, endotoxin) were missing, immunogenicity could not be ruled out for subcutaneous products, no clinical safety or pharmacokinetic data existed, no study measured sleep outcomes, and FDA-approved and OTC insomnia treatments exist. On 2026-07-24 the Pharmacy Compounding Advisory Committee voted in favour of inclusion; published accounts agree on 7 votes in favour but differ on the number against (4 or 5), and official minutes had not been posted when this was written. Rulemaking is required before any change takes effect.
